Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
The company is built around RAS-targeted oncology, and their daraxonrasib has become one of the most closely watched assets in that space. The stock's momentum has only strengthened the strategic case. Barron's reported on April 13 that Revolution Medicines shares had already gained 164% over the prior year before jumping another 39% that day after new trial data. Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data Pressmaster/Shutterstock.com The catalyst was daraxonrasib's pivotal Phase 3 RASolute 302 result announced on April 13, 2026. Reuters reported that the drug helped previously treated metastatic pancreatic cancer patients live a median of 13.2 months, compared with 6.7 months for standard chemotherapy, while also improving progression-free survival. RBC said the drug could eventually generate more than $5 billion in U.S. sales. Daraxonrasib's strategic value had already drawn takeover attention. On January 8, 2026, Reute
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]TheStreet.com
- Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswire
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- RVMD's page on the SEC website